Compounding Problems for Weight Loss: A Look at Novo Nordisk’s Legal Battles with Pharmacies over Semaglutide

This article was authored by Matt Quinn, Ph.D., Research Consultant. Semaglutide belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists that have been utilized clinically for the treatment of Type II diabetes and obesity. Ozempic is Novo Nordisk’s FDA-approvedRead More